Blueprint Medicines Corporation

As of March 31, 2025, Blueprint Medicines Corporation has 64.56M shares outstanding.

These figures are as of March 31, 2025. The price-to-sales ratio is 10.00, and the price-to-book ratio stands at -2.33.

These figures are as of March 31, 2025. The EV/Sales ratio of 9.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Blueprint Medicines Corporation trades at an EV/FCF ratio of 2.68, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2025, Blueprint Medicines Corporation maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 136.41, indicating elevated leverage, while an interest coverage ratio of -2.21 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2025. Return on assets (ROA) is negative at -13.94, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -106.97, pointing to unprofitable operations over the period. Inventory turnover of 0.90 indicates how many times Blueprint Medicines Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended March 31, 2025. That works out to an effective tax rate of 61.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on July 18, 2025, Blueprint Medicines Corporation's stock has gained approximately 14.10% over the past 52 weeks. The 50-day moving average sits at 118.77, while the 200-day moving average is 99.62.

Over the twelve months ended March 31, 2025, Blueprint Medicines Corporation posted a gross margin of 96.48, reflecting its pricing power and cost economics. The operating margin of -31.01 and net profit margin of -27.70 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield is negative at -2.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.83, meaning Blueprint Medicines Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2025, Blueprint Medicines Corporation has an Altman Z-Score of 1.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.